In this week's edition...
 
— MFN would import access restrictions – hear Paula’s story. Click here to view Paula's story.
 — Roll Call: Bipartisan call for Congress to ban metric that devalues people with disabilities. View the Roll Call opinion here. View the Open Letter here from over 100 groups. View PIPC's one pager here. 
— Florida Bill Would Import QALYs, Devalue People with Disabilities. Learn more about the experiences of patients and people with disabilities in other countries here. View the letter from PIPC here. View a constituent letter from The Speak Foundation here.
— States Renew Attack on Section 504 of the Rehabilitation Act and the Integration Mandate. Click here to read more.
— EACH/PIC Coalition Version 2.0 of Patient Experience Survey: Prescription Drug Affordability and Unaffordability. Learn more here.
 — Survey Shows Virginia Voters Trust Doctors and are Skeptical of PDABs. Click here to view.
— PIPC Responds to CMS' GLOBE and GUARD Models, Also Known as 'Most Favored Nation.' Click here to read PIPC's full statement.
— RealClear Discusses 'Most Favored Nation,' Criticizing the Policy's Impact on Patient Access. Click here to view the article.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

Color of Gastrointestinal Illnesses (COGI) sent a letter to the Florida House and Senate expressing concerns about a pair of bills that would import discriminatory value assessment metrics. 

In this week's edition...
 
— Roll Call: Bipartisan call for Congress to ban metric that devalues people with disabilities. View the Roll Call opinion here. View the Open Letter here from over 100 groups. View PIPC's one pager here. 
— Florida Bill Would Import QALYs, Devalue People with Disabilities. Learn more about the experiences of patients and people with disabilities in other countries here. View the letter from PIPC here. View a constituent letter from The Speak Foundation here.
 — Survey Shows Virginia Voters Trust Doctors and are Skeptical of PDABs. Click here to view.
— PIPC Responds to CMS' GLOBE and GUARD Models, Also Known as 'Most Favored Nation.' Click here to read PIPC's full statement.
— RealClear Discusses 'Most Favored Nation,' Criticizing the Policy's Impact on Patient Access. Click here to view the article.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below
— Upcoming Events and Webinars. See details below.

The SPEAK Foundation sent a letter to the Florida House and Senate expressing concerns about a pair of bills that would import discriminatory value assessment metrics. 

This piece originally ran in Roll Call on January 15, 2026

Now more than ever, we need to listen to and respect one another’s views and values, whether on the floor of Congress or in individual health care decisions. ​

In this week's edition...
 
— PIPC Responds to CMS' GLOBE and GUARD Models, Also Known as 'Most Favored Nation.' Click here to read PIPC's full statement.
— RealClear Discusses 'Most Favored Nation,' Criticizing the Policy's Impact on Patient Access. Click here to view the article.
— MFN May Also Cut Off Rural America. Click here to view the article.
— The Well News (Opinion): Most Favored Nation Drug Pricing Fails Patients and their Caregivers. View the opinion here.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— PIPC Chairman Coelho Testifies to Oregon Department of Consumer and Business Services. View Chairman Coelho’s testimony here. View the testimony from Disability Rights Oregon here. Learn more about the hearing here.
— White House Issues RFI on Scientific Research & AI. See details below.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

​In this week's edition...
 
— PIPC Responds to CMS' GLOBE and GUARD Models, Also Known as 'Most Favored Nation.' Click here to read PIPC's full statement.
— RealClear Discusses 'Most Favored Nation,' Criticizing the Policy's Impact on Patient Access. Click here to view the article.
— MFN May Also Cut Off Rural America. Click here to view the article.
— The Well News (Opinion): Most Favored Nation Drug Pricing Fails Patients and their Caregivers. View the opinion here.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— PIPC Chairman Coelho Testifies to Oregon Department of Consumer and Business Services. View Chairman Coelho’s testimony here. View the testimony from Disability Rights Oregon here. Learn more about the hearing here.
— White House Issues RFI on Scientific Research & AI. See details below.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

​PIPC appreciates the administration’s goals to lower health costs for patients. PIPC remains concerned that the latest proposals to advance a Most Favored Nation pricing model for drugs will, in effect, import the worst of foreign health systems – their reliance on discriminatory value assessments. Stories from outside the U.S., like that of the Williams’ family, illustrate why quality-adjusted life years (QALYs) have no place in U.S. policy. Patients do not have the luxury of time.

In this week's edition...
 
— The Well News (Opinion): Most Favored Nation Drug Pricing Fails Patients and their Caregivers. View the opinion here.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— PIPC Responds to Medicare Negotiation Program’s Prices. View PIPC’s complete statement here. 
— PIPC Chairman Coelho Testifies to Oregon Department of Consumer and Business Services. View Chairman Coelho’s testimony here. View the testimony from Disability Rights Oregon here. Learn more about the hearing here.
— White House Issues RFI on Scientific Research & AI. See details below.
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

​The recent draft Health Technology Assessment (HTA) methods report released by the Health Economics Methods Advisory group makes it crystal clear – policy grounded in conventional HTA methods (like the QALY) are willing to harm the individual for the sake of the formula-derived average. 

PIPC shared the following statement highlighting its appreciation for the Trump Administration’s goal of lowering health care costs for patients awhile sharing continued concerns over the subjectivity and lack of transparency in the process for selecting a Maximum Fair Price (MFP), limited consideration of patient perspectives, and potential for continued reliance on value assessments conducted by the Institute for Clinical and Economic Review. 

In this week's edition...
 
— PIPC Responds to Medicare Negotiation Program’s Prices. View PIPC’s complete statement here. 
— White House Issues RFI on Scientific Research & AI. See details below.
— Oregon Invites ICER to Hearing on Pricing Despite Statewide QALY Ban. More information is available here.
— Draft HEMA Report: USC Schaeffer Makes Case Against Accepting Individual Harms to Improve Population Averages. View USC Schaeffer’s response to the draft report here.
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— New PQA Patient Advisory Council Seeks Nominations. Individuals can submit their nominations via this form. Additional details are provided in a recent PQA blog.
— PCORI Discusses the Importance of Patient-Centered Comparative CER Research. Click here to read more.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— New PQA Patient Advisory Council Seeks Nominations. Individuals can submit their nominations via this form. Additional details are provided in a recent PQA blog.
— Draft HEMA Report: USC Schaeffer Makes Case Against Accepting Individual Harms to Improve Population Averages. View USC Schaeffer’s response to the draft report here.
— PCORI Discusses the Importance of Patient-Centered Comparative CER Research. Click here to read more.
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
-- The Baltimore Sun: Maryland's Drug Affordability Board Has Been a Failure. View the opinion here. 
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

The Partnership to Improve Patient Care (PIPC) has issued the following statement in response to the Trump administration's "GENEROUS" model. 

In this week's edition...
 
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
— ICER Again Fails to Address Patient and Disability Concerns Related to its Biased Methodology. View PIPC’s Data Mine blog related to the methodology and protocol here.
-- The Baltimore Sun: Maryland's Drug Affordability Board Has Been a Failure. View the opinion here. 
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— PharmaPhorum Discusses the Affordability of Medicines and Innovation. Click here to read the article.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.